Genmab A/S (GMAB) Stock
GMAB Key Statistics
About Genmab A/S
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
CEO: Jan van de Winkel. Company website
GMAB — Frequently Asked Questions
What is the GMAB stock price today?
Genmab A/S (GMAB) trades at $34.74, up 0.61% on the day, as of Sep 20, 2026 15:00 UTC.
What is Genmab A/S's market cap?
Genmab A/S has a market capitalisation of $21.33B, calculated from the live GMAB share price and shares outstanding.
What is the P/E ratio of GMAB?
GMAB trades at a trailing P/E of 27.35, from earnings per share of $1.27 over the last twelve months.
How much revenue does Genmab A/S make?
Genmab A/S generated revenue of $4.13B over the trailing twelve months, which puts the stock at 5.16 times sales.
What is the 52-week range for GMAB?
GMAB has traded between $23.62 and $35.43 over the past 52 weeks, and the last price is 1.9% below that high.
Is Genmab A/S profitable?
Yes. Genmab A/S keeps 8.17% of revenue as net income over the trailing twelve months.
What is the analyst price target for GMAB?
Wall Street analysts rate GMAB Buy, with an average price target of $38.25, 10.1% above the current price.
What sector is Genmab A/S in?
Genmab A/S is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in DK.
Who is the CEO of Genmab A/S?
Jan van de Winkel is the chief executive of Genmab A/S, which employs 3,119 people.
Where can I track GMAB in real time?
QFI Terminal shows GMAB with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See GMAB live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open GMAB in Terminal See plans